Predicting risk in patients with acetaminophen overdose. Expert Rev Gastroenterol Hepatol 2013 Aug;7(6):509-12
Date
08/30/2013Pubmed ID
23984999Pubmed Central ID
PMC4124995DOI
10.1586/17474124.2013.814901Scopus ID
2-s2.0-84887840045 (requires institutional sign-in at Scopus site) 5 CitationsAbstract
Acetaminophen (APAP) overdose is a very common cause of drug overdose and acute liver failure in the US and Europe. Mechanism-based biomarkers of APAP toxicity have the potential to improve the clinical management of patients with large-dose ingestions of APAP. The current approach to the management of APAP toxicity is limited by imprecise and time-constrained risk assessments and late-stage markers of liver injury. A recent study of 'low-risk' APAP overdose patients who all received treatment with N-acetylcysteine found that cell death biomarkers were more sensitive than alanine aminotransferase (ALT) and APAP concentrations in predicting the development of acute liver injury. The data suggest a potential role for new biomarkers to identify 'low-risk' patients following APAP overdose. However, a practical and ethical consideration that complicates predictive biomarker research in this area is the clinical need to deliver antidote treatment within 10 h of APAP overdose. The treatment effect and time-dependent nature of N-acetylcysteine treatment must be considered in future 'predictive' toxicology studies of APAP-induced liver injury.
Author List
James LP, Gill P, Simpson PAuthor
Pippa M. Simpson PhD Adjunct Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AcetaminophenChemical and Drug Induced Liver Injury
Female
HMGB1 Protein
Hospitalization
Humans
Keratin-18
Male
MicroRNAs